By Connor Hart
Shares of Silexion Therapeutics surged after the company released what it called promising preclinical data for its treatment of pancreatic cancer.
The stock jumped 68%, to $2.61, in after-hours trading Wednesday. Shares ended the regular session 12% lower, at $1.56, putting them down more than 98% in the last year.
The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer.
Additional preclinical data show that the drug exhibits synergistic activity with 5-fluorouracil and irinotecan--two main components commonly used in pancreatic-cancer treatments--when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer, the company said.
Moving forward, Silexion said it will continue developing SIL-204. It plans to initiate toxicology studies with the drug within the upcoming months, as well as advance it into Phase 2/3 clinical trials in the first half of 2026.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 15, 2025 18:05 ET (23:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。